Back

Impact of Providing Future Cardiovascular Risk Based on Genetic Testing on Low-Density Lipoprotein Cholesterol in Patients with Familial Hypercholesterolemia (GenTLe-FH): A Randomized Wait-list Controlled Open-Label Trial

Nomura, A.; Okada, H.; Nohara, A.; Kawashiri, M.-a.; Takamura, M.; Tada, H.

2023-03-27 cardiovascular medicine
10.1101/2023.03.26.23287767
Show abstract

Background and AimsFamilial hypercholesterolemia (FH) is an autosomal dominant monogenic disease characterized by high low-density lipoprotein cholesterol (LDL-C) levels. Although carrying causative FH variants is associated with coronary heart disease (CHD), it remains unclear whether disclosing its associated cardiovascular risk affects outcomes in patients with FH. Here, we evaluated the efficacy of providing future cardiovascular risk based on genetic testing in addition to a standard FH education program. MethodsWe conducted a randomized, wait-list controlled, open-label, single-center trial. In the intervention group, we reported a future cardiovascular risk based on the genetic testing adding to standard FH education at week 0. In the wait-list control group, we only disseminated standard FH education according to the guidelines at week 0; they later received a genetic testing-based cardiovascular risk assessment at week 24. The primary endpoint of this study was the plasma LDL-C level at week 24. ResultsFifty eligible patients with clinically diagnosed FH, without a history of CHD, were allocated to the intervention group (n=24) or the wait-list control group (n=26). At week 24, the intervention group had a significantly greater reduction in LDL-C levels than the wait-list control group (mean changes, -13.1 mg/dL vs. 6.6 mg/dL; difference, -19.7 mg/dL; 95% confidence interval, -34 to -5.6; p=0.009). This interventional effect was consistent with FH causative variant carriers but not with non-carriers. ConclusionsIn addition to standard FH care, providing future cardiovascular risk based on genetic testing can further reduce plasma LDL-C levels, particularly among FH causal variant carriers. RegistrationJapan Registry of Clinical Trials (jRCTs04218002). URL: https://jrct.niph.go.jp/latest-detail/jRCTs042180027

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Circulation: Genomic and Precision Medicine
based on 30 papers
Top 0.3%
12.8%
2
Journal of the American Heart Association
based on 92 papers
Top 3%
10.0%
3
Atherosclerosis
based on 16 papers
Top 0.2%
10.0%
4
Circulation
based on 37 papers
Top 1%
7.5%
5
European Journal of Preventive Cardiology
based on 12 papers
Top 0.1%
6.3%
6
Frontiers in Cardiovascular Medicine
based on 33 papers
Top 3%
4.4%
50% of probability mass above
7
European Heart Journal
based on 14 papers
Top 1%
4.4%
8
PLOS ONE
based on 1737 papers
Top 73%
4.4%
9
Open Heart
based on 18 papers
Top 2%
2.9%
10
The American Journal of Cardiology
based on 15 papers
Top 2%
2.8%
11
Arteriosclerosis, Thrombosis, and Vascular Biology
based on 11 papers
Top 0.9%
2.4%
12
International Journal of Cardiology
based on 13 papers
Top 2%
2.3%
13
Hypertension
based on 20 papers
Top 2%
2.2%
14
eLife
based on 262 papers
Top 16%
1.7%
15
Journal of Clinical Medicine
based on 77 papers
Top 10%
1.6%
16
BMC Cardiovascular Disorders
based on 11 papers
Top 2%
1.6%
17
BMC Medicine
based on 155 papers
Top 16%
1.3%
18
BMJ Open
based on 553 papers
Top 45%
1.3%
19
Journal of the American College of Cardiology
based on 11 papers
Top 2%
1.3%
20
International Journal of Obesity
based on 17 papers
Top 2%
1.2%
21
JMIR Research Protocols
based on 18 papers
Top 2%
1.2%
22
Heliyon
based on 57 papers
Top 14%
0.7%
23
PLOS Medicine
based on 95 papers
Top 18%
0.7%
24
Journal of Personalized Medicine
based on 17 papers
Top 3%
0.7%
25
Scientific Reports
based on 701 papers
Top 87%
0.7%